secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001104659-23-060256
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health Q1 net revenue drops 25% YoY to $2.0M; OnTarget top line due Oct 2023
--------------------------------------------------------------------------------

- Net revenue $2.0M, down 25% YoY from $2.6M and 40% QoQ from $3.3M.
- Net loss to common stockholders improved to $12.2M from $18.0M YoY; EPS –$2.39 vs –$23.10.
- PIPE closed raising ~$1.86M; no equity issuance before Oct 22, 2023 under agreement.
- Phase 3 OnTarget trial enrollment completed; top line results expected October 2023.
- IND submission for crofelemer in MVID planned Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923060256/0001104659-23-060256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923060256/tm2315707d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-060256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer